A Pilot Study of Low-Cost, High-Resolution Microendoscopy as a Tool for Identifying Women with Cervical Precancer by Pierce, Mark C. et al.
A pilot study of low-cost, high-resolution microendoscopy as a
tool for identifying women with cervical precancer
Mark C Pierce1,*, YaoYao Guan2,*, Mary Kate Quinn3, Xun Zhang4, Wen-Hua Zhang4, You-
Lin Qiao4, Philip Castle5, and Rebecca Richards-Kortum3
1Rutgers, The State University of New Jersey, Dept. of Biomedical Engineering, Piscataway NJ
2Johns Hopkins University School of Medicine, Baltimore MD
3Rice University, Dept. of Bioengineering, Houston TX
4Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China
5American Society for Clinical Pathology, Washington DC
Abstract
Cervical cancer remains one of the leading causes of death among women in developing countries.
Without resources to support Pap smear cytology and colposcopy, cost-effective approaches
which enable single-visit “see-and-treat” protocols offer the potential to reduce morbidity and
mortality due to this preventable disease. We carried out a pilot clinical study in Shanxi province,
China, to evaluate a low-cost, high-resolution microendoscope (HRME) imaging system which
enables evaluation of epithelial cell morphology in vivo. HRME images were obtained at discrete
sites on the cervix in 174 women, in addition to visual inspection with acetic acid (VIA), and
colposcopic examination. Out of 69 sites appearing abnormal on colposcopy, only 12 showed
high-grade disease (CIN2+) on pathology. Quantification of the nuclear-to-cytoplasm ratio by
HRME enabled an ad hoc threshold to be defined, which correctly classified all 12 sites as
abnormal, whilst classifying 38 of the remaining 57 pathology normal sites as normal. All patients
with biopsy confirmed high-grade disease also tested positive for high-risk HPV DNA, and were
classified as abnormal by HRME. Among the remaining patients who tested positive for HPV but
were either normal by colposcopy or showed < CIN2 on pathology, only 6/32 (18.8%) were
classified as abnormal by HRME.
Visual examination techniques for cervical cancer screening may overestimate the prevalence of
precancerous lesions, leading to unnecessary treatment, expense, and patient stress. The results of
this study suggest that evaluation of suspicious lesions by HRME may assist in ruling out
immediate cryotherapy, thus increasing the efficiency of current see-and-treat programs.
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Introduction
Cervical cancer is the third most common cancer amongst women worldwide; an estimated
530,000 new cases occurred and 275,000 women died from this treatable disease in 2008
(1). Over 80% of these cases occur in developing countries (2), which lack the resources and
expertise required to maintain the regular screening programs used in industrialized nations.
In low-resource settings, techniques such as visual inspection with acetic acid (VIA) or with
Lugol's iodine (VILI) have been proposed as cost-effective alternatives to traditional Pap /
cytology programs for cervical cancer screening. In several large clinical studies, VIA has
demonstrated clinical sensitivity ranging from 41%–92%, approaching that of standard
colposcopy (3–5). Such methods have enabled “see-and-treat” programs to be implemented,
using cryotherapy for immediate ablation of any lesion appearing abnormal by VIA. The
ability to deliver diagnostic and therapeutic services in a single clinic visit is a key factor in
reducing patient loss to follow-up after a positive screening test, which can amount to 15%
of patients, or more when a multi-visit screening approach is required (6).
While the sensitivity of VIA / VILI is quite good, some studies have reported specificity
figures as low as 49% (7). Poor specificity, along with the potential for loss to follow-up,
has raised concerns that see-and-treat programs using VIA / VILI may lead to over-
treatment of many benign conditions which do not represent significant cervical cancer risk
and will resolve without intervention. Over-treatment raises the expense of these programs
and may cause unnecessary concern for the patient. In the absence of colposcopically-guided
biopsy collection with histopathology processing and review, new approaches are required
to identify those patients who genuinely require treatment. Optical imaging and
spectroscopy techniques have been shown to detect alterations in tissue morphology and
biochemistry within epithelial and stromal tissue components, associated with the onset and
progression of cervical neoplasia (8–10). Macroscopic optical imaging (similar to standard
colposcopy) examines an entire organ surface under white light, narrow-band illumination,
and/or under conditions required for fluorescence excitation. In contrast, microscopic optical
imaging involves placement of the tip of a small fiber-optic probe directly onto the cervical
epithelium, enabling individual cells to be visualized in vivo (11). By using exogenous
contrast agents such as acetic acid or acriflavine / proflavine, morphologic features used by
pathologists such as nuclear crowding, pleomorphism, and nuclear-to-cytoplasm ratio can be
assessed in vivo and in real-time (12,13).
We describe here the results of a pilot clinical study using a recently-developed low-cost
microscopic imaging system, termed the high-resolution microendoscope (HRME) (14), for
evaluation of cervical lesions appearing abnormal under VIA or colposcopy. Our long-term
hypothesis is that HRME imaging can improve the specificity of early detection of cervical
cancer and its precursors by ruling out many of the visually or colposcopically apparent
lesions that are actually benign. Here, we set out to establish whether HRME can identify
cervical lesions which do not require treatment in patients initially screened by VIA or HPV
testing. Reducing the numbers of lesions treated unnecessarily following visual examination
or colposcopy would clearly benefit the patient, while also lowering the overall costs of see-
and-treat programs in the settings where their impact is greatest.
Materials and Methods
Study population
Institutional Review Boards at each of the clinical sites and academic institutions involved,
including Johns Hopkins University, the Chinese Academy of Medical Sciences, and Rice
University, approved the study. A total of 2,500 women over 18 years of age living in
Xiangyuan County, China underwent initial VIA / VILI examination as part of their
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involvement in the national cancer screening program. Based on prior data from the
program, it was estimated that 4% of this cohort would receive a positive VIA / VILI test
result (Fig. 1a). As a nested pilot study to evaluate HRME, patients with an abnormal VIA /
VILI exam (n = 63) were invited to participate in this study, along with a random selection
of patients with a normal VIA / VILI exam (n = 111). The imaging portion of the study was
completed in August 2010. The mean, median, interquartile range, and total range of age for
the 174 subjects were 41 years, 41 years, 36–45 years, and 29–58 years, respectively.
Study procedures
The 174 participants were offered transportation from their local villages to the Xiangyuan
County Maternal and Child Health Hospital of Shanxi, where the study was conducted (Fig.
1b). Each participant had an initial one-on-one interview with a trained health worker, where
basic demographic information (age, education, etc.), past medical / gynecological history,
family history, HPV knowledge assessment, and other behavioral factors (transportation
method, access to medical care, etc.) were collected. The interview was conducted in the
local Chinese dialect.
After the initial interview, a clinician collected a cervical exfoliated cellular (Pap) sample
for HPV testing using a Qiagen cervical sampler brush (Qiagen, Gaithersburg, MD, USA)
and a Whatman indicating FTA elute cartridge (GE Healthcare, United Kingdom). Next, a
second VIA examination was performed, this time by the study clinician, and the location of
any abnormal appearing lesion was recorded. Each patient then immediately underwent a
standard colposcopic examination, performed by the same clinician, again with the location
of any abnormal appearing lesions recorded. Proflavine solution was then topically applied
to the cervix (Fig. 2b). HRME imaging immediately followed, with gentle placement of the
fiber-optic probe tip directly onto the site of interest (Fig. 2c). All colposcopically abnormal
lesions were imaged with HRME, in addition to one colposcopically normal site per patient.
Figure 2d shows the HRME image obtained with the probe placed at the site indicated in
Fig. 2c. The imaged field-of-view is a 720 μm wide en face view, corresponding to the area
of tissue beneath the diameter of the fiber-optic probe tip. A biopsy was taken at each
colposcopically abnormal site and immediately placed in fixative for standard
histopathology processing. Colposcopic identification of lesions, HRME probe placement
and imaging, and biopsy collection were all performed within a single examination, by the
same clinician, in an attempt to co-register measurement sites. Slides with H&E stained
tissue sections were prepared at the Xiangyuan County Women's and Children's Hospital,
China and read by the study pathologist. The entire imaging portion of the study was
typically completed in 5 minutes. .
HPV testing
Cervical specimens were also tested for 37 HPV genotypes using the Roche HPV linear
array test (Roche Diagnostics, Indianapolis, IN) at Johns Hopkins University, as previously
described (15). Patients were considered positive for high-risk HPV (HR-HPV) if their test
was positive for any of the high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, and/or 68).
Colposcopy
Biopsies were obtained from all lesions which were visually apparent under colposcopy.
Specimens were processed for histopathology and graded by the study pathologist as
normal, cervical intraepithelial neoplasia grade 1 (CIN1), grade 2 (CIN2), grade 3 (CIN3),
or cancer (SCC).
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High-resolution microendoscopy
Immediately prior to imaging with the HRME, topical proflavine solution (0.01% w/v in
sterile phosphate buffered saline) was applied to the cervix with a Q-tip, similar to
application of acetic acid in standard colposcopy. Proflavine is a fluorescent contrast agent
which selectively stains cell nuclei. The dye strongly absorbs blue light with an optical
absorption peak at a wavelength of 445 nanometers, producing green fluorescence emission
with a peak wavelength of 515 nanometers. Once the dye was applied, patients immediately
underwent HRME imaging; no additional incubation period was necessary. Technical details
on the high-resolution microendoscope (HRME) design and assembly have been described
previously in Pierce et al. (14). Briefly, the system operates as a compact, battery-powered
fluorescence microscope, coupled to a flexible fiber-optic imaging probe, 1 mm in diameter
(Fig. 2a). Blue light provided by a light-emitting diode (LED) at a wavelength of 455 nm is
delivered from the HRME unit, through the fiber-optic probe, to the tissue surface.
Fluorescence from proflavine-stained epithelium is transmitted back through the same probe
to the HRME unit and imaged onto a CCD camera. Images are displayed on a laptop
computer screen in real-time at 12 frames per second. The fiber-optic probe used in the
current study provides a 0.72 mm diameter field-of-view with 4.4 μm resolution. After
imaging each patient, the fiber-optic probe was disinfected with Cidex OPA, according to
the manufacturer's instructions (Johnson & Johnson).
Data analysis
HRME images of proflavine-stained tissue primarily reveal cell nuclei as discrete bright dots
on a dark background. To quantify parameters related to nuclear morphology, image
analysis software was written (Matlab, R2010b) to automatically identify nuclei, based on
their characteristic size, shape, and brightness in HRME images. Raw grayscale images were
subject to an adaptive histogram equalization algorithm to optimize contrast across the entire
field-of-view, followed by a two-dimensional median filter to reduce the appearance of the
fiber-optic probe's internal structure. A binary image was then generated by applying a
single user-defined intensity threshold to a user-selected region-of-interest in each image,
leaving pixels with original values above the threshold as “1”, and pixels below the
threshold as “0”. Morphological processing then removed small objects (noise) and large
objects (clumps) before labeling each group of connected “1” pixels as unique objects and
documenting their properties (location, size, outline). Each object was considered to be an
individual cell nucleus. The average nuclear-to-cytoplasm (“N/C”) ratio for each image was
calculated by dividing the total number of image pixels identified as nuclei, by the total
number of pixels (minus nuclei and eliminated clumps) within the region-of-interest.
Examples of this image processing procedure are shown in Supplemental Figure S1.
Prior to quantitative image analysis, each HRME image underwent a quality-control review
by one of the study investigators (MP), which removed images from the data pool if any of
the following criteria were met: (1) The focused portion of the HRME image occupied less
than half of the available field-of-view, (2) there was excessive loose tissue or debris in the
field of view, (3) there was cellular material / debris visibly adhered to the fiber tip.
Results
Visually apparent lesions were noted both by VIA and colposcopy in 62 patients, while VIA
and colposcopic examinations were negative in 111 patients. No VIA or colposcopic
impression was recorded for one patient and the HRME data obtained from this patient were
not analyzed further. One hundred ninety-five unique cervical sites were imaged in the
remaining 173 patients. Seventy-nine of these sites were at colposcopically abnormal lesions
in 62 patients. The remaining sites were at colposcopically normal locations in the
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remaining 111 patients. Figure 2 presents the colposcopic appearance and HRME images
from abnormal appearing sites in two different patients. In Fig. 2e, the acetowhite region at
5 o'clock was considered abnormal by the colposcopist. Following placement of the fiber-
optic probe onto this site, HRME imaging revealed nuclei appearing as discrete dots,
sparsely and evenly distributed throughout the field-of-view, characteristic of normal
squamous epithelium (Fig. 2f). Following biopsy, the pathology diagnosis for this site was
non-neoplastic. A second patient with a lesion considered abnormal under standard
colposcopy at the 12 o'clock location (Fig. 2g) also underwent HRME imaging. In the
HRME image (Fig. 2h), nuclei appear more crowded and unevenly spaced, with some loose
debris and mucus within the field-of-view. The histopathologic diagnosis at this site was
CIN3.
We calculated N/C ratio values for each of the 69 colposcopically abnormal sites which
passed the quality control review (10 sites were eliminated by QC review). These sites were
biopsied on the basis of colposcopic appearance, therefore enabling comparison of HRME-
derived N/C ratio values against the histopathologic diagnosis. We also established the N/C
ratio at one imaged site in each of 95 colposcopically normal patients (images from 16 out
of these 111 patients were eliminated by QC). These sites were not biopsied and therefore
only permit comparison of N/C ratio to colposcopic appearance. Figure 3a shows the
individual N/C ratio values measured at each of the 69 sites with a pathology diagnosis, as
well as the 95 colposcopically normal sites imaged. Figure 3b shows the mean ± standard
error values for N/C ratios at each pathology grade. The 12 lesions diagnosed as CIN 2/3/
SCC had higher mean and median N/C ratios than each of the lower-grade categories.
Combining all diagnoses less severe than CIN 2 into a single category (median N/C = 0.164)
and comparing to the CIN 2 or more severe diagnosis (median N/C = 0.251) indicated that
the mean ranks of the N/C ratio values are significantly different for these two groups
(Kruskal-Wallis, p = 1.3601 × 10−4).
Figure 3a also shows a horizontal dashed line representing a post-hoc N/C ratio threshold
value of 0.185, which was the lowest value that correctly classified all 12 CIN2+ sites as
“neoplastic”. Using this threshold, 38 out of 57 sites considered abnormal by colposcopy
(and therefore biopsied) were correctly classified as non-neoplastic by HRME, based on
their histopathologic diagnoses (open markers below the threshold in Fig. 3a). Nineteen out
of these 57 sites with a pathology grade of normal or CIN1 were incorrectly classified by
HRME as abnormal (open markers above the N/C = 0.185 threshold in Fig. 3a). When the
same threshold was applied to the colposcopically normal (and not biopsied) sites (Fig. 3a),
only 8 out of the 95 sites exhibited an N/C figure above 0.185.
Table 1 summarizes the fraction of sites classified as neoplastic by HRME vs. histologic
diagnosis, also stratified by colposcopic impression. Only 8.4% of sites with a normal
colposcopic impression were classified as neoplastic by HRME. All histologically neoplastic
sites (CIN2+) were identified correctly by HRME. Of the 54 colposcopically abnormal sites
with benign histology (false positive by colposcopy), only 35% were classified as neoplastic
by HRME.
Table 2 summarizes the fraction of patients classified as neoplastic by HRME vs. histologic
diagnosis, this time stratified by whether the patient tested positive for high-risk HPV. Nine
patients had histologically confirmed disease (CIN2+); all nine tested positive for HR-HPV
and also had an N/C ratio above the 0.185 threshold on HRME. Among women who were
colposcopically normal or had a pathology diagnosis of < CIN2, there was no difference in
the percentage that had a HRME N/C ratio above 0.185 for those who were HR-HPV
negative (19/133 = 14.3%) and those who were HR-HPV positive (6/32 = 18.8%), (p = 0.6,
Fisher's exact test).
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Discussion
Through improvements in our knowledge of the pathogenesis of cervical cancer, the disease
is now mostly preventable, but still disproportionately affects women living in developing
countries. Screening and treatment approaches based on cervical cytology have been
successful in reducing the burden of cervical cancer where effective programs have been
established. However, attempts to establish such programs in lower-resource settings, which
experience over 80% of the burden of cervical cancer incidence and mortality, have been
largely unsuccessful. Several new tools have emerged that may help to address these
disparities, including HPV vaccination, lower-cost HPV DNA testing, visual inspection
methods, and ablative treatment (16). The use of VIA with cryotherapy has enabled see-and-
treat programs to be implemented in several countries, providing women with the
opportunity for cervical screening and treatment to be completed in a single clinic visit.
However, there remains concern regarding the real possibility of significant over-treatment
based on VIA-positive results, with a similar concern for management of HPV-positive
women participating in HPV test-based screening. This study evaluated a recently-
developed low-cost imaging device which provides real-time information on cervical cell
morphology in vivo. Such information may prove complementary to existing and emerging
tools for diagnosis of cervical cancer and precancerous lesions in low-resource settings. Our
primary goal in this study was to evaluate whether HRME imaging could potentially be used
to improve the specificity of visual inspection using either colposcopy or VIA.
Visually apparent lesions with a pathology diagnosis of CIN2 or higher exhibited more
crowded nuclei, often with greater variation in nuclear size and separation than at sites
graded as CIN1 or normal / benign. A post-hoc single threshold value of nuclear-to-
cytoplasm area ratio discriminated between sites with non-neoplastic and neoplastic
pathology with 100% sensitivity (12 out of 12 with CIN2+) and 67% specificity (38 out of
57 with colposcopically positive lesions, but < CIN2 on pathology). Significantly, the 57
pathologically non-neoplastic sites were all deemed sufficiently abnormal in appearance
under VIA / colposcopy to warrant biopsy collection, a false positive rate of 57/69 = 83%.
Over two-thirds of those unnecessary biopsies were identified as non-neoplastic by HRME
imaging. Of the 19 colposcopically abnormal sites which were incorrectly classified by
HRME as abnormal against a gold-standard of pathology, the majority of these false positive
sites (17/19) showed chronic inflammation, either alone or with metaplasia (Fig. 3a). Given
the generally high prevalence of inflammation in patients in low-resource settings, such
conditions may impact the accuracy of HRME in these populations. However, the results
reported here from China suggest that HRME may improve specificity over VIA alone,
whilst emphasizing the need for further evaluation in populations with even higher
prevalence of inflammation.
When patients were initially stratified based on a positive high-risk HPV DNA test, HRME
image analysis correctly identified 100% of patients with CIN2 or more severe disease (9
out of 9 patients). Of the 30 patients with a positive high-risk HPV test but no histologic (11
patients < CIN2) or colposcopic (21 patients) evidence of disease, only 6 patients (18.8%)
were identified as neoplastic by HRME imaging. These data support the potential for HMRE
imaging to be used as an adjunct diagnostic tool in settings where HPV testing provides the
initial screening result.
While reducing the amount of unnecessary biopsies can reduce program costs, the HRME
system used in this study requires an up-front investment of around $3,000, the majority of
this cost being allocated to the imaging camera. We have also evaluated lower-cost
consumer-grade cameras that retail for around $300 and have confirmed their suitability for
use in HRME system (17). HRME is not the first in vivo cellular-level imaging technique to
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be evaluated for detecting cervical neoplasia. The use of confocal microscopy, in reflectance
and fluorescence modes has been reported previously with promising results. The study by
Tan et al. (13) demonstrated the ability of confocal fluorescence microscopy to also
visualize nuclear morphology in the cervical epithelium following topical application of
acriflavine dye (proflavine, the dye used in the study described here, is the fluorescent
component of acriflavine). The authors developed a set of qualitative criteria which readers
could apply to each image to assist in reaching a diagnostic decision. In a prospective study
of 15 tissue sites, each with an independent pathology diagnosis, readers achieved 97%
sensitivity and 93% specificity in identifying sites classified by pathology as CIN2 or
higher. We note that the descriptive criteria developed by Tan et al. were entirely based on
features related to nuclear morphology, and could be directly applied to images generated by
the HRME system in real-time. HRME images also display an area of tissue 2.5-times larger
at a frame rate 6-times faster than that of the confocal platform used by Tan et al., which
may also improve diagnostic performance and ease of use. An assessment of training
methods and learning curve for users of HRME was not directly included within this study,
though it may be noted that all image data were acquired by clinical staff with no prior
experience of HRME imaging. We have found that HRME images can be accurately
classified as neoplastic / non-neoplastic by clinicians using qualitative criteria in other organ
sites (18,19). However, we demonstrated here the ability to objectively classify images using
quantitative analysis of features such as N/C ratio, thereby reducing the degree of subjective
interpretation required by the user. Future studies will more thoroughly assess these
important questions which will impact uptake of this technology.
While the HPV vaccine has immense potential to positively impact cancer prevention
programs, particularly in low-resource settings, early detection techniques will still have key
roles to play. The cost of the vaccine is declining but may remain unacceptably high in some
regions. Current HPV vaccines target the two types, HPV16 and 18, which are only
responsible for 70% of cervical cancers. Even when a suitably priced vaccine becomes
widely available and is given to adolescents, it will take decades for the impact of
vaccination to become clear. Women who have already been exposed to HPV and will not
benefit from HPV vaccination, and those who are have not been vaccinated will still require
screening, ideally at between 30–45 years of age (20,21).
The limitations of this study include a design which did not exactly reflect the intended use
of the HRME in practice (i.e. as an adjunctive diagnostic tool for use in triaging VIA+ or
HPV+ cases). However, this pilot study was carried out to permit evaluation of a relatively
large VIA− and HPV− population that will certainly be encountered in the field. These data
will require validation in a larger, well-powered, prospective trial that permits objective
evaluation and establishment of HRME image features, including the optimum N/C ratio
threshold for classifying tissue as neoplastic.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
(Left) Design of the pre-screening phase of the study. The study was designed to accrue an
estimated 100 patients with cervical precancerous lesions, and 100 normal patients. (Right)
Design of the HRME evaluation study. A total of 174 patients were recruited to the study
from the pre-screening phase.
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Figure 2.
(a) Photograph of the high-resolution microendoscope (HRME) system and (b–d)
demonstration of the imaging procedure. (b) Proflavine is applied using a cotton-tipped
swab; (c) the fiber-optic probe is placed in gentle contact with the cervix; and (d) a high-
resolution image is displayed on a laptop computer in real time. (e) Colposcopic view of an
aceto-white cervical lesion at 5 o'clock (arrow), and (f) resulting HRME image. Histologic
diagnosis of this site was normal, consistent with the HRME image which shows small,
evenly spaced nuclei. (g) Colposcopic view of another aceto-white cervical lesion at 12
o'clock (arrow), and (h) resulting HRME image. Histologic diagnosis of this site was CIN3,
consistent with the HRME image which shows large, crowded, pleomorphic nuclei. HRME
image scale bars = 100 µm.
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Figure 3.
(a) Individual N/C ratio values measured at each of the 69 sites with a pathology diagnosis,
as well as the 95 colposcopically normal sites imaged. The dashed line represents a post-hoc
threshold at the lowest value which correctly classified all 12 CIN2+ sites as “neoplastic”.
(b) Mean ± standard error values for N/C ratios at each pathology grade.
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Table 1
Fraction of sites classified positive by HRME image analysis vs. colposcopic impression and histologic
diagnosis
Colposcopic impression Histologic diagnosis # Sites measured # Sites HRME positive % Sites HRME positive
Normal No biopsy 95 8 8.4%
Abnormal
Normal / Benign 54 19 35%
CIN 1 3 0 0%
CIN 2 7 7 100%
CIN 3 3 3 100%
scc 2 2 100%
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Table 2
Fraction of sites classified positive by HRME image analysis vs. high-risk HPV test status and histologic
diagnosis.
High risk HPV status Histologic diagnosis # Patients measured # Patients HRME positive % Patients HRME positive
HR HPV −
No biopsy 90 5 5.6%
Normal / benign 43 14 32.6%
HR HPV +
No biopsy 21 2 9.5%
Normal / benign 9 4 44.4%
CIN1 2 0 0%
CIN2 6 6 100%
CIN3 2 2 100%
scc 1 1 100%
Note that no patients who were negative for high-risk HPV types had a biopsy with a diagnosis of CIN (any grade) or SCC.
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